Cendakimab ELISA Kit

Catalog No.

KDE07703

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

78.125 - 5,000 ng/mL

Sensitivity

33.12 ng/mL

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

13C5.5,ABT-308,RPC-4046, CAS: 2151032-62-9

Pharmacokinetic Characterization of Cendakimab Administered with Different Devices and at Different Injection Sites in Healthy Participants., PMID:40374841

New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review., PMID:40281872

IL-13 inhibition in the treatment of atopic dermatitis - new and emerging biologic agents., PMID:39558725

Design of a phase 3, randomized, double-blind, placebo-controlled, 48-week study to evaluate the efficacy and safety of cendakimab in adult and adolescent patients with eosinophilic esophagitis., PMID:39384067

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial., PMID:39018038

Histological Outcomes of Pharmacological Interventions in Eosinophilic Esophagitis for Adults and Children: A Network Meta-analysis of Randomized Controlled Trials., PMID:38701235

The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs., PMID:38338983

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab., PMID:37310643

Biologic Therapies Targeting Eosinophilic Gastrointestinal Diseases., PMID:37081678

Emerging therapies for eosinophilic esophagitis., PMID:36840634

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis., PMID:36839890

Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis., PMID:36647838

Biologics in eosinophilic gastrointestinal diseases., PMID:35738437

Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis., PMID:35505944

Drug treatment strategies for eosinophilic esophagitis in adults., PMID:35379069

Current options and investigational drugs for the treatment of eosinophilic esophagitis., PMID:35072575

Targeted Therapies for Eosinophilic Gastrointestinal Disorders., PMID:32472465

Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis., PMID:32205221

One If By Steroids and Two If By Biologic., PMID:30641052

RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis., PMID:30395812

RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study., PMID:28455782

Document Download

Cendakimab ELISA Kit.pdf